File patents now before changes introduce uncertainty
This article was originally published in Scrip
A key element of the America Invents Act (AIA) is Section 3, which brings the US more into line with Europe and other patent jurisdictions by moving from a 'first-to-invent' regime to a 'first-to-file' regime. This comes into effect on 16 March 2013 (scripintelligence.com, 30 July 2012; 19 September 2011; 12 September 2011) . With the big shift looming, Scrip spoke to Otis Littlefield, a partner with law firm Morrison & Foerster specializing in patent prosecution, about how companies should be preparing for the change.
You may also be interested in...
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.